NEWS COMMENTARY

Evonik partners with the Center for Microbiome Innovation at UCSD in search for new raw cosmetics materials

Published:
August 29, 2019
Coverage:
Accelerating Materials Innovation More...
Activities:
Partnership More...
by Kristin Marshall
Average importance

After releasing its first skin microbiome-targeted product in 2018, Evonik is intensifying efforts to understand the complex ecosystem of microbes living on the skin. As a result, Evonik hopes to improve its existing cosmetic raw materials and inform the development of new ones. The company is just one of several cosmetic raw material suppliers taking steps to accelerate skin microbiome R&D in recent years, recognizing the impact such capabilities can have on product development. Clients supplying raw materials into the BPC market should not wait to get involved. Given that skin microbiome-targeted products are already on the market, those that choose to "wait and see" will fall even further behind their peers over the next two years.

For the original news article, click here .


Further Reading

Strategies for Synbio Success

State of the Market Report | December 31, 2019

Synthetic biology (synbio) has high potential as an alternate production route for chemicals, with emerging applications in agrifood, beauty and personal care, chemicals, and consumer products. However, effectively using synbio capabilities requires understanding the right strategy for each of the ... Not part of subscription

BASF leverages AI to rapidly design novel bioactive ingredients derived from plant proteins

Case Study | March 19, 2019

BASF is a key player in the materials and chemicals industry, with diverse business units. The company's Nutrition unit focuses on developing solutions for human nutrition, including novel ingredients for food and supplement applications. Developing novel ingredients with specific bioactive ... Not part of subscription

Fitbiomics demonstrates how bacteria from marathon runners can serve as a probiotic to enhance athletic performance

News Commentary | June 28, 2019

When Lux last spoke with Fitbiomics in September 2018, we gave it a Lux Take of "Wait and See," citing its need to validate efficacy. Through the study, researchers were able to demonstrate that mice given the athlete‑derived probiotic (Veillonella) could run 13% longer than the control group. The ... Not part of subscription